FDA Grants Novavax Emergency Use Authorization for Covid-19 Booster
October 19 2022 - 11:55AM
Dow Jones News
By Kathryn Hardison
Novavax Inc. has received emergency use authorization from the
U.S. Food and Drug Administration for its protein-based Covid-19
booster for adults.
The vaccine has been approved as a first booster dose for people
of at least 18 years of age who received a primary Covid-19
vaccination at least six months prior, the biotechnology company
said Wednesday.
The booster is authorized for adults without access to an
FDA-authorized mRNA bivalent booster vaccine and for adults who
would otherwise not receive a booster, the company said.
The next step is a policy recommendation for use as a first
booster from the Centers for Disease Control and Prevention,
Novavax said.
The vaccine also is available for use as a booster in adults
aged 18 and older in the European Union, Japan, Australia, New
Zealand, Switzerland and Israel.
Write to Kathryn Hardison at kathryn.hardison@wsj.com
(END) Dow Jones Newswires
October 19, 2022 11:40 ET (15:40 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024